Uncategorized

Exubera Update, Roche Reports

This morning Pfizer (NYSE:PFE) provided an updated status for the launch of their inhaled insulin product Exubera. Here’s what we learned today: A. A. Physician and patient education will begin July 24, 2006 and be rolled out in phases. B. B. Initial supplies of Exubera will be available in September. C. C. Starter kits that will be used in the education phase should be available...

Integrity of reporting

Two stories that appeared in today’s Wall Street Journal show just how difficult it is to provide accurate, unbiased information. The first appeared on page one of the Marketplace section, “Medical Reviews Face Criticism Over Lapses” which covered the continuing issue over proper disclosure of financial interests. Just last week, the Journal of the American Medical Association published a correction indicating that seven authors of a February paper on depression...

Abbott reports 2nd Quarter Results with a Navigator update

This morning Abbott (NYSE:ABT) announced their second quarter 2006 results and reiterated their belief that their continuous glucose monitor Navigator will receive FDA approval in the second half of this year. The company also mentioned they are closing in on taking over second place, in terms of market share, in the US blood glucose monitoring market. According to the company they now hold 20% of the domestic BGM market. ...

The return of the non-invasive glucose monitor

Yesterday afternoon NIR Diagnostics Inc. (TSX Venture: NID) announced in a press release, “achieved a level of accuracy in sponsored feasibility testing of its light-based in vitro glucose monitoring device that is sufficient to advance to development of a prototype and initiate clinical trials.” The release goes to state, “Achieving results of more than 90 percent in the A zone and 99.5 percent in the A and B zone of...

The return of the non-invasive glucose monitor

Yesterday afternoon NIR Diagnostics Inc. (TSX Venture: NID) announced in a press release, “achieved a level of accuracy in sponsored feasibility testing of its light-based in vitro glucose monitoring device that is sufficient to advance to development of a prototype and initiate clinical trials.” The release goes to state, “Achieving results of more than 90 percent in the A zone and 99.5 percent in the A and B zone of...

JNJ Results and what they mean for the entire glucose monitoringmarket

This morning Johnson and Johnson (NYSE:JNJ) reported 2006 second quarter results which showed LifeScan sales increasing 14% in the United States and 5% Internationally for the quarter. On a year to date basis LifeScan sales are up 10% domestically and flat internationally. It should be noted that this is the first reporting period which incorporates JNJ’s acquisition of insulin pump maker Animas. It would difficult to characterize LifeScan’s results...

More evidence

This morning Becton Dickinson (NYSE:BDX) announced results for the New York City BD Diabetes Makeover Program. According to a press release issued by the company; “The New York City participants completed the intensive 11-week portion of their program on Saturday, June 24, 2006. All participants realized a significant decrease in blood glucose values as measured by A1C in a 3-month period of time and experienced a trend toward normalization of...

More problems for Roche’s insulin pump unit

Yesterday Disetronic, the insulin pump company now a part of Roche, announced a voluntary nationwide recall of D-TRONplus power packs used in D-TRONplus insulin pumps. According to a press release issued by the company, “There is the real potential that the power pack could shut down the D-TRONplus Insulin Pump without any warning. If a shut down occurs, insulin delivery is interrupted. An interruption in insulin delivery may lead to...

Good stocks in a bad market

While Diabetic Investor does not necessarily like to make market calls, this is best left for the experts to get wrong; this summer is proving to be a difficult time. Oil prices continue to rise and it seems as though the Middle East tensions are once again building. The war in Iraq goes on while North Korea and Iran continue to saber rattle. To some this just might be the...

Bayer buys Metrika

“Metrika, the maker of the at home A1c test A1cNow+ is in the midst of serious late stage negotiations to be acquired. Although all the I’s aren’t dotted nor are the T’s crossed, the deal should be closed in the very near future. While there is more than on suitor Diabetic Investor sees Bayer coming out on top.” These comments came from an email alert Diabetic Investor sent out back...